| 초록 |
Glioblastoma multiforme is the most aggressive malignant brain tumor in human beings. Recently, to cure GBM clinically, antiangiogenic therapy with medications such as Avastin is tried to slow the GBM growth. However, this drug can induce some side effects like stroke and kidney problem. In this study, we newly developed a orally absorbable heparin which has antiangiogenic activity via binding with growth factors around the tumor tissue. To this end, lactoferrin, a globular glycoprotein represented in secretory fluids, was chemically conjugated with heparin. It was no cytotoxicity (Caco-2 cell monolayer system) and had antiangiogenic activity in vitro. When Lf-heparin was orally treated in the mice, it absorbed in the small intestine via Lf receptor-mediated transcytosis. In addition, it could be targeted to the brain tissue due to the existence of Lf receptor on the blood-brain barrier. Collectively, this Lf-heparin bioconjugate could be used to treat GBM as a new oral medication. |
